These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15817697)

  • 1. Modeling and simulation of cancer immunoprevention vaccine.
    Pappalardo F; Lollini PL; Castiglione F; Motta S
    Bioinformatics; 2005 Jun; 21(12):2891-7. PubMed ID: 15817697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico modeling and in vivo efficacy of cancer-preventive vaccinations.
    Palladini A; Nicoletti G; Pappalardo F; Murgo A; Grosso V; Stivani V; Ianzano ML; Antognoli A; Croci S; Landuzzi L; De Giovanni C; Nanni P; Motta S; Lollini PL
    Cancer Res; 2010 Oct; 70(20):7755-63. PubMed ID: 20924100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
    Chan T; Sami A; El-Gayed A; Guo X; Xiang J
    Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario.
    Astolfi A; Rolla S; Nanni P; Quaglino E; De Giovanni C; Iezzi M; Musiani P; Forni G; Lollini PL; Cavallo F; Calogero RA
    Cancer Immunol Immunother; 2005 Jun; 54(6):599-610. PubMed ID: 15690207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of vaccine's schedules using models.
    Pappalardo F; Motta S; Lollini PL; Mastriani E
    Cell Immunol; 2006 Dec; 244(2):137-40. PubMed ID: 17442286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy.
    De Giovanni C; Nicoletti G; Landuzzi L; Croci S; Palladini A; Antognoli A; Murgo A; Ianzano ML; Grosso V; Stivani V; Iezzi M; Musiani P; Nanni P; Lollini PL
    Vaccine; 2009 Mar; 27(14):2065-9. PubMed ID: 19428831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of cancer vaccination protocols with a genetic algorithm driving an agent based simulator.
    Lollini PL; Motta S; Pappalardo F
    BMC Bioinformatics; 2006 Jul; 7():352. PubMed ID: 16857043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors.
    Tegerstedt K; Lindencrona JA; Curcio C; Andreasson K; Tullus C; Forni G; Dalianis T; Kiessling R; Ramqvist T
    Cancer Res; 2005 Jul; 65(13):5953-7. PubMed ID: 15994974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma.
    Smorlesi A; Papalini F; Amici A; Orlando F; Pierpaoli S; Mancini C; Provinciali M
    Vaccine; 2006 Mar; 24(11):1766-75. PubMed ID: 16288939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimetastatic activity of a preventive cancer vaccine.
    Nanni P; Nicoletti G; Palladini A; Croci S; Murgo A; Antognoli A; Landuzzi L; Fabbi M; Ferrini S; Musiani P; Iezzi M; De Giovanni C; Lollini PL
    Cancer Res; 2007 Nov; 67(22):11037-44. PubMed ID: 18006850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
    Sas S; Chan T; Sami A; El-Gayed A; Xiang J
    Cancer Gene Ther; 2008 Oct; 15(10):655-66. PubMed ID: 18421311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
    Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
    Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines.
    Singh R; Paterson Y
    Cancer Immunol Immunother; 2007 Jun; 56(6):927-38. PubMed ID: 17131121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
    Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
    Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
    Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
    J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination for treatment and prevention of cancer in animal models.
    Cavallo F; Offringa R; van der Burg SH; Forni G; Melief CJ
    Adv Immunol; 2006; 90():175-213. PubMed ID: 16730264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis.
    Lewēn S; Zhou H; Hu HD; Cheng T; Markowitz D; Reisfeld RA; Xiang R; Luo Y
    Cancer Immunol Immunother; 2008 Apr; 57(4):507-15. PubMed ID: 17786443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.